Results 121 to 130 of about 161,983 (298)

Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges

MedComm – Oncology
As the largest microecosystem in the human body, gut microbes (GMs) and their metabolites play an important role in regulating human health. In recent years, immune checkpoint therapy (ICT) combined with antiangiogenic agents is an emerging combination ...
Jie Xu, Yaomei Tian, Die Hu, Xi Yan, Li Yang   +4 more
doaj   +1 more source

Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

Oncoimmunology, 2017
Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs).
J. Pitt, Marie Vetizou, Ivo Gomperts Boneca, P. Lepage, M. Chamaillard, L. Zitvogel   +5 more
semanticscholar   +1 more source

The temporal trends and short‐ and long‐term mortality of people with acute myocardial infarction and rheumatoid arthritis: a nationwide cohort study

Arthritis Care &Research, Accepted Article.
Aims We investigated whether a diagnosis of rheumatoid arthritis (RA) affects the quality of inpatient acute myocardial infarction (AMI) care and long‐term mortality post‐AMI. Methods We analysed data from 784,091 adults, 6,047 with a diagnosis of RA, from England and Wales hospitalised with AMI between 2005 and 2019 from the MINAP registry, linked ...
Megan Butler, Nicholas Weight, Muhammad Rashid, Rodrigo Bagur, Purvi Parwani, Samantha Hider, Edward Roddy, Robert Butler, Mamas A Mamas   +8 more
wiley   +1 more source

Anti-TNF, a magic bullet in cancer immunotherapy?

Journal for ImmunoTherapy of Cancer, 2019
Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs).
Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, Bruno Ségui   +9 more
doaj   +1 more source

Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study (Preprint)

, 2023
María A. López-Olivo, María E. Suarez‐Almazor, Gabrielle F. Duhon, McKenna Erck, Huifang Lu, Cassandra Calabrese, Mehmet Altan, Hussein A. Tawbi, Alexa Meara, Clifton O. Bingham, Adi Diab, Viola B. Leal, Robert J. Volk   +12 more
openalex   +1 more source

Combinatorial Approaches with Checkpoint Inhibitors to Enhance Anti-Tumor Immunity as Advantages of Targeting the Tumor Immune Microenvironment over Blocking Immune Checkpoint in Cancer Immunotherapy [PDF]

, 2021
Elena Locci, Silvia Raymond
openalex   +1 more source

Immune Checkpoint Blockade: The New Frontier in Cancer Treatment

Targeted oncology, 2018
Immune checkpoint blockers have revolutionized cancer treatment in recent years. These agents are now approved for the treatment of several malignancies, including melanoma, squamous and non-squamous non-small cell lung cancer, renal cell carcinoma ...
J. Clarke, D. George, S. Lisi, A. Salama
semanticscholar   +1 more source

A Smart Bio‐Battery Facilitates Diabetic Bone Defect Repair Via Inducing Macrophage Reprogramming and Synergistically Modulating Bone Remodeling Coupling

Advanced Functional Materials, EarlyView.
This research presents a novel implantable bio‐battery, GF‐OsG, tailored for diabetic bone repair. GF‐OsG generates microcurrents in high‐glucose conditions to enhance vascularization, shift macrophages to the M2 phenotype, and regulate immune responses.
Nanning Lv, Haifu Sun, Wenxiang Tang, Yonggang Li, Zhonglai Qian, Lihui Hong, Chong Chen, Hongye Li, Jiaxiang Bai, Yusen Qiao, Mingming Liu   +10 more
wiley   +1 more source

Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis [PDF]

, 2023
Michael P. O’Shea, Suganya Arunachalam Karikalan, Ali Yusuf, Timothy Barry, Eiad Habib, J.Conor O’Shea, Michael Killian, Eman Javed Baqal, Srishti Nayak, Rajeev Masson, Joerg Hermann, Shimoli Shah, Chadi Ayoub, Hicham El Masry   +13 more
openalex   +1 more source

Bimetallic Nanoreactor Activates cGAS‐STING Pathway via mtDNA Release for Cancer Metalloimmunotherapy

Advanced Functional Materials, EarlyView.
A bimetallic Mn–Ca nanoreactor (MCC) is developed as a non‐nucleotide STING nanoagonist for cancer metalloimmunotherapy. MCC induces Ca2+ overload and hydroxyl radical generation, resulting in mitochondrial damage and mtDNA release. The released mtDNA cooperates with Mn2+ to robustly activate cGAS–STING signaling.
Xin Wang Mo, Nguyen Thi Nguyen, LiLi Guo, Ngoc Man Phan, Hyunsu Shin, Tae‐il Kim, Yu Seok Youn, Jaeyun Kim   +7 more
wiley   +1 more source